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Summary
Colorectal cancer (CRC) is global problem with 1.36 million new cases each year. Moreover it is the third most com-
mon cancer in men worldwide (746,000; 10%) and second most common in women (614,000 cases; 9.2%). The main charac-
teristic of colorectal cancer is slow development and long presympthomatic phase, so it make possible for early diagnose as 
well as prevention by removing polyps. Faecal occult blood testing (FOBT) for early detection of colorectal cancer is an evi-
dence based, cost-effective screening strategy and is the most commonly chosen approach in organised population-based 
colorectal cancer screening programmes throughout the world. There are two main kinds of tests-one guaiac based which 
detects hem in haemoglobin and other, immunochemical directed to detect protein part globuline. All FOBT positive per-
sons are sent to colonoscopy. CRC incidence and mortality data in Croatia still show high values, especially in males so 
national colorectal cancer screening programme started in Croatia under the auspices of the Ministry of Health and Welfare 
(now the Ministry of Health) at the end of 2007. All citizens age 50-74 years are invited to programme. First cycle lasted 
longer due to legal and financial difficulties related to the harmonization of legislation with EU law and finished in 2012. 
Response rate was 21%, so the second cycle started in September 2013thin reorganized form which includes educational and 
promotive campaign and participation of primary care physicians and field nurses.
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EPIDEMIOLOGIJA I PROBIR KOLOREKTALNOG KARCINOMA
Sa`etak
Rak debelog crijeva globalni je problem s 1.36 milijuna novih slu~ajeva svake godine. [tovi{e, u mu{karaca je to tre}e 
naju~estalije sijelo (746,000; 10%) i drugo u `ena (614,000 cases; 9.2%). Glavna osobina raka debelog crijeva je spori razvoj 
bolesti i dugo razdoblje do pojave prvih znakova, {to ga ~ini pogodnim za rano otkrivanje kao i prevenciju uklanjanjem 
polipa. Testiranje na skrivenu krv u stolici za rano otkrivanje kolorektalnog raka je utemeljeno na dokazima i kost-u~inkovita 
je strategija, pa je naj~e{}i pristup provedbom organiziranih populacijskih programa diljem svijeta. Dvije su glavne vrste 
testova na skrivenu krv u stolici-gvajakov koji otkriva hem u hemoglobinu i imunokemijski temeljen na reakciji s globulin-
skim dijelom. Sve osobe s pozitivnim testom upu}uju se na kolonoskopjiju. Pojavnost i smrtnost od raka debelog crijeva u 
Hrvatskoj jo{ uvijek pokazuju visoke vrijednosti, osobito u mu{karaca, te je 2007. god. zapo~eo nacionalni program ranog 
otkrivanja u organizaciji Ministarstva zdravlja. Svi gra|ani u dobi 50-74 godine pozivaju se u program. Prvi ciklus trajao je 
dulje od planiranog zbog zakonskih i financijskih problema vezanih uz harmonizaciju zakona sa zakonima EU, te je zavr{io 
2012. godine. Odaziv je bio 21%, a drugi ciklus po~eo je u rujnu 2013. u reorganiziranom obliku {to uklju~uje edukacijsku i 
promotivnu kampanju te u~e{}e obiteljskih lije~nika i patrona`nih sestara.
KLJU^NE RIJE^I: epidemiologija, kolorektalni karcinom, mortalitet, probir




Colorectal cancer (CRC) is an important health 
issue throughout the world. The latest estimates 
of the International Agency for Research on Can-
cer (IARC) according to GLOBOCAN 2012 (1) are 
point to 1.36 million new cases of CRC in the world 
each year, 447,000 of which occur in Europe. It is 
the third most common cancer in men worldwide 
(746,000; 10%) and second most common in wom-
en (614,000 cases; 9.2%). There is a substantial geo-
graphical variation in the incidence and mortality 
rates, with the highest incidence rates attributable 
to Australia and New Zealand while the highest 
mortality rates are observed in Central and East-
ern Europe. Incidence has been on the rise in re-
cent years, owing to the rise of overall life expec-
tancy and lifestyle changes related to diet factors. 
The most common risk factors include high fat 
and red meat consumption with low vegetable in-
take, overweight and obesity, physical inactivity 
and high consumption of alcohol (2). Family his-
tory of colorectal cancer is also an important pre-
disposition for development of CRC, accounting 
for 15-20% of all cases (3), with hereditary syn-
dromes accounting for 5% of the cases (4).
In Croatia, a recent publication revealed in-
creasing trends in incidence and mortality of CRC 
in men in the period 1988-2008, with estimated an-
nual percent changes (EAPC) of +2.9% for inci-
dence and +2.1% for mortality. In women, the in-
crease in incidence rates was not statistically sig-
nificant, while mortality rates showed an increase 
for the period from 1994-2008, with the EAPC of 
+1.1% (5).
The most recent data for Croatia (incidence 
for 2011 (6); mortality for 2012 (7) show that, in 
males, colorectal cancer is ranked third in inci-
dence (1.648 new cases; crude incidence rate 
79.8/100,000) and second in cancer causes of death 
(1.136 deaths; crude mortality rate 55.0/100,000). 
In females, colorectal cancer is ranked second in 
incidence (1.172 new cases; crude incidence rate 
52.8/100.000) and second in cancer related mortal-
ity (868 deaths; crude mortality rate 39.1/100,000). 
The distribution of stages for CRC registered in 
the Croatian Cancer Registry in 2011 indicates that 
it was diagnosed at the localised stage in 19% of 
cases, with regional spreading or regional metas-
tases in 39% of the cases, in 22% there were distant 
metastases at time of diagnosis, while for 20% of 
the cases the information on stage at diagnosis 
was missing.
According to the latest GLOBOCAN 2012 es-
timates, in males in Europe, Croatia is ranked 8th 
in incidence (age-standardized rate (ASR(W)) 
44.2/100,000) and 3rd in mortality (ASR(W) 26.7/
100,000). For women, Croatia is ranked 16th in inci-
dence (24.7/100,000) and 2nd in mortality (ASR(W) 
13.0/100,000). The estimated 5-year prevalence is 
293.3/100,000 in males and 204.8/100,000 in fe-
males (1).
The recently published EUROCARE-5 study 
has provided data on cancer survival in European 
countries, and for the first time Croatian data were 
also included. The study showed that the 5-year 
relative survival of Croatian cancer patients diag-
nosed from 2000-2007 and followed-up until the 
end of 2008 was 49.6% for colon cancer, and 48.5% 
for rectal cancer (both sexes combined) (8). This 
was lower than survival in western European 
countries (Austria 61.2%/61.1%, Denmark 53.6%/
54.6%), comparable to similar European countries 
(Slovenia 54.0%/49.7%, Slovakia 51.4%/44.7%) 
and higher than survival in Eastern European 
countries such as Bulgaria (45.2%/38.4%) and Lat-
via (42.9%/36.1%).
Colorectal cancer screening
The main characteristic of colorectal cancer is 
slow development and long presympthomatic 
phase. A growth of tissue or tumor usually begins 
as a non-cancerous polyp on the inner lining of the 
colon or rectum and if not treated it can develop to 
Figure 1 Stage at diagnosis in CRC patients diagnosed in 2011, 
Source: Croatian National Cancer registry (6)
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Figure 2 Incidence and mortality of colorectal cancer in Europe, Source: GLOBOCAN 2012 (1)
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malignant lesion (9). The chance of changing into 
a cancer depends upon the kind of polyp, so ade-
nomatous polyps can change into cancer and are 
called a pre-cancerous condition. Hyperplastic 
polyps and inflammatory polyps, in general, are 
not pre-cancerous. But some studies show that 
some hyperplastic polyps can become pre-cancer-
ous or might be a sign of having a greater risk of 
developing adenomas and cancer, particularly 
when these polyps grow in the ascending colon 
(10). Another kind of pre-cancerous condition is 
called dysplasia. Dysplasia is an area in the lining 
of the colon or rectum where the cells look abnor-
mal (but not like true cancer cells) when viewed 
under a microscope. These cells can change into 
cancer over time. Dysplasia is usually seen in peo-
ple who have had diseases such as ulcerative coli-
tis or Crohn’s disease for many years. Both ulcer-
ative colitis and Crohn’s disease cause chronic in-
flammation of the colon (9).
Faecal occult blood testing (FOBT) for early 
detection of colorectal cancer is an evidence based, 
cost-effective screening strategy and is the most 
commonly chosen approach in organised popu-
lation-based colorectal cancer national and regio-
nal screening programmes throughout the world 
(11, 12).
Early detection of disease or screening in the 
healthy population is one way of improving 
health, and also the basis of epidemiology as a 
profession which aims preventing diseases in 
population or target group. The diseases that have 
a relatively long period between the beginning of 
the disease development and the first signs, and if 
there is an appropriate test for the early detection, 
it is possible and reasonable to implement screen-
ing (13). Test or examination that is used must also 
satisfy the criteria for clinical validity (correspond-
ing sensitivity and specificity), and the risk of ex-
amination shall be the minimum and must be safe 
for the patient. It is important to have a robust 
digitalized system for monitoring patients and 
screening procedures for assessment (14). The fi-
nal result of screening must be absolute prolonga-
tion of life not just earlier detection of disease (15). 
Moreover, the ultimate goal of every screening is 
reducing mortality and improving quality of life 
for patients, so quality care must be provided as 
well as treatment of newly diagnosed patients. 
There is scientifically based and multi-practically 
confirmed evidence that screening for colorectal 
cancer contributes to early and timely detection, 
and consequently to greater survival as well as 
improved quality of life for patients, which is very 
important (16). A satisfactory response according 
to EU quality assurance guidelines is 45%, and the 
desired 65% (14). It should be noted that in some 
countries only after 10 or more years of implemen-
tation the response rate has been increased to 25%, 
but in countries with already developed knowl-
edge of the population about the usefulness of 
prevention or those countries with extensive edu-
cational and promotional campaign, a significant 
increase of the response rate is as it has been done 
in the neighbouring Slovenia (17).
According to the recommendations of the 
Council of the European Union (2003/878/EZ), 
and based on published data and experience at 
that time, the national colorectal cancer screening 
programme started in Croatia under the auspices 
of the Ministry of Health and Welfare (now the 
Ministry of Health) at the end of 2007. The pro-
gram is implemented in accordance with the reso-
lution on the prevention and control of cancer 
(WHA, 58.22, Cancer prevention and control), ad-
opted by the World Health Assembly at its 58th 
session in Geneva 2005th.
The network of Public Health Institutes, the 
Croatian National Institute of Public Health, hos-
pitals, clinics, polyclinics and primary health care 
are included in implementation of the program. 
The first cycle lasted longer due to legal and finan-
cial difficulties related to the harmonization of 
legislation with EU law (from 2008-2012.) In Sep-
tember 2013th the second cycle started in the reor-
ganized form.
The objectives of the Croatian National Colorectal 
Cancer Screening Program
Program objectives are to detect cancer in its 
beginning stages, detect and remove polyps of the 
colon and thereby increase the possibility of heal-
ing, and improve the quality of life for affected 
individuals. Furthermore, the aim is to strengthen 
the network of colonoscopy units and to improve 
the organization of the program. So, the target is 
to increase the current response. The long-term 
goal is to reduce the mortality of colorectal cancer 
by 15% , 10-13 years after the start of the pro-
gram.
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Target Group
The target group for this screening program 
are all women and men aged 50-74 years (approx-
imately 1,400.000 persons). One cycle of invita-
tions lasts 2 years.
Method
Guaiac-based hypersensitive FOB test is used 
to test the occult (hidden) blood in the stool. For 
persons who have positive FOBT, a colonoscopy 
is a method of making a definitive diagnosis but 
also treatment in the event of finding polyps.
The organization of the first cycle
In the first cycle of the program implementa-
tion it was organized in such a way that the test-
cards were sent to the home addresses of the 
members of target population. The respondents 
received three test-cards and were asked to take 
samples of their stool successively for three con-
secutive days and send back in the enclosed enve-
lope. The analysis of the samples was conducted 
in the Public Health Institutes. Persons whose test 
findings were positive were then invited for colo-
noscopy. The invitation also included a referral 
voucher and instructions on how to prepare for 
colonoscopy.
Results of the first cycle
In the first cycle a samples from 1,419.639 
persons were received for testing, among those 
15,339 people were ineligible for testing. The Insti-
tutes received 288,935 of the sent test packages 
(21%) with correctly applied specimens which is 
in accordance to the response rate according to EU 
guidelines (17.2 to 70.8% ) in the first round.
Within the program, more than 10,000 colo-
noscopy examinations were conducted (80% re-
sponse rate) and 576 people with colon cancer 
were discovered (2.3‰ of total number of tested 
persons, which is consistent with the expected: EU 
guidelines 1.2-2,3/1000). In 4223 people polyps 
were found (39.7% of incurred colonoscopy) and 
removed.
Changes during the reorganization process 
of the program
The reorganization of the program aims to 
increase the response rate and at the same time 
raise the level of knowledge and awareness of the 
population about colon cancer. The reorganiza-
tion of the program is done due to rationalization, 
and in the first phase public health institutes send 
invitation letters, and then send test packages to 
responders who want it. We created a series of ac-
tivities aimed at improving the organization and 
quality of the program. Written protocols that 
specify the basic epidemiological indicators of the 
quality control and indicators of implementation 
results are an obligatory part of the program. The 
European guidelines for quality assurance of 
screening are translated and will be published 
soon on the web. Coordinators in public health in-
stitutes (specialists in epidemiology and public 
health) within their teams are responsible for 
monitoring and implementation of the first part of 
the diagnostic process, as well as a timely provi-
sion of colonoscopy appointments for positive pa-
tients and for collaboration on continuous quality 
improvement program. They also participate in 
the organization of educational and promotional 
activities throughout Croatia. A very important 
factor for the successful implementation is con-
tinuous education of the personnel, i.e. profes-
sionals who are specifically trained to implement 
screening. Other measures for increasing partici-
pation rates are also implemented (i.e. napkins 
that can be placed on the toilet seat, clear and sim-
ple instructions for test performance as well as 
bowel cleaning and preparation for colonoscopy 
etc.).
Figure 3. toilet-seat napkin for easy stool sampling
CONCLUSIONS
In the upcoming period we plan to strength-
en the implementation and ongoing promotional 
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educational campaign organized by the Ministry 
of Health, Institutes of Public Health and the as-
sociations of interested patients, of which the most 
important one in Croatia is ILCO, association of 
patients with colostomy.
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